Literature DB >> 8318672

Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia.

S Cohen-Kaminsky1, O Devergne, R M Delattre, I Klingel-Schmitt, D Emilie, P Galanaud, S Berrih-Aknin.   

Abstract

Most patients with Myasthenia Gravis (MG) present a thymic hyperplasia characterized by the presence of lymphoid follicles. The acetylcholine receptor autoantigen, as well as autoantigen specific activated T and B cells found in the thymus, strongly suggest that auto-sensitization could take place in this organ. Since IL-6 is involved in T and B cell growth and differentiation, we thought that abnormal IL-6 expression by thymic epithelial cells (TEC) could be related to thymic hyperplasia in MG. In this paper, IL-6 protein and gene expression by cultured TEC from patients with MG were examined. TEC from patients presented a dramatic IL-6 hyperproduction phenotype as compared to controls when stimulated by exogenous signals such as LPS and cytokines (IL-1 beta, TNF-alpha) alone or in combination. Moreover, we observed a similar effect with a physiological signal such as the syngeneic lympho-epithelial cell contact. Autologous thymocytes stimulated normal and MG TEC IL-6 production in a time- and dose- dependent way, and with a higher magnitude in MG TEC compared to controls. In all stimulation conditions, induction of IL-6 production required protein synthesis and was associated with increased IL-6 mRNA level expression as assessed by computer-aided quantification after in situ mRNA hybridization. In addition, recombinant IL-6 induced in vitro growth of TEC, demonstrating that IL-6 is a possible autocrine growth factor for these cells. This deregulated IL-6 production as well as the ability of TEC to use it as a growth factor may be of pathophysiological relevance in MG. It provides an explanation for morphological changes of the thymus and may have a key role in initiation, exacerbation and ongoing of the autoimmune response in MG. Therefore this study extends our current understanding of the molecular pathophysiology of MG.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318672

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  7 in total

Review 1.  Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review.

Authors:  Frédérique Truffault; Vincent de Montpreville; Bruno Eymard; Tarek Sharshar; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

2.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis.

Authors:  Anna Balandina; Sandrine Lécart; Philippe Dartevelle; Abdelhadi Saoudi; Sonia Berrih-Aknin
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

Review 3.  Imbalance of regulatory T cells in human autoimmune diseases.

Authors:  Christian Dejaco; Christina Duftner; Beatrix Grubeck-Loebenstein; Michael Schirmer
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

4.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

5.  Inflammation and epstein-barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis.

Authors:  Paola Cavalcante; Lorenzo Maggi; Lara Colleoni; Rosa Caldara; Teresio Motta; Carmelo Giardina; Carlo Antozzi; Sonia Berrih-Aknin; Pia Bernasconi; Renato Mantegazza
Journal:  Autoimmune Dis       Date:  2011-09-26

6.  NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.

Authors:  Tehila Mizrachi; Livnat Brill; Malcolm Rabie; Yoram Nevo; Yakov Fellig; Mayan Zur; Dimitrios Karussis; Oded Abramsky; Talma Brenner; Adi Vaknin-Dembinsky
Journal:  J Immunol Res       Date:  2018-05-22       Impact factor: 4.818

Review 7.  New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.

Authors:  Anthony Behin; Rozen Le Panse
Journal:  J Neuromuscul Dis       Date:  2018
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.